ライフサイエンスコーパス: interleukin-23

1 autoantibodies against interleukin-23 (anti-interleukin-23).

2 going chronic inflammation and production of interleukin 23.

3 nt and correlated with reduced production of interleukin 23.

4 he receptor for the proinflammatory cytokine interleukin-23.

5 0%) also had autoantibodies that neutralized interleukin-23.

6 monoclonal antibody, binds to subunit p19 of interleukin-23.

7 representative scaffolds and panned against interleukin-23.

8 hemokine genes, including the p19 subunit of interleukin-23.

9 ed levels of tumor necrosis factor alpha and interleukin-23.

10 discovery of the biological functions of the interleukin-23/-17 axis led to the identification of IL-

11 Interleukin-23, a recently described cytokine produced b

12 i infection, the identification of both anti-interleukin-23 and anti-interleukin-12 prompted further

13 subunit inhibitor that potently neutralises interleukin-23 and can bind to CD64.

14 ependent on inflammatory DCs, which produced interleukin-23 and increased fatty acid oxidation.

15 b, an antibody that binds the p40 subunit of interleukin-23 and interleukin-12 and thereby blocks the

16 Monoclonal antibodies targeting interleukin-23 and interleukin-12 are efficacious in tre

17 Inhibition of interleukin-23 and interleukin-17 may have a role in the

18 expressed high levels of interleukin-1beta, interleukin-23 and interleukin-6, and promoted T-helper

19 cts of lipopolysaccharide on interleukin-12, interleukin-23, and matrix metalloproteinase-9, suggesti

20 on involving high-mobility group protein B1, interleukin-23, and the Th17 pathway.

21 r modulators, interleukin 12/23 or selective interleukin 23 antagonists, and Janus kinase [JAK] inhib

22 t dominates the binding affinity for an anti-interleukin-23 (anti-IL-23) antibody by using the comple

23 n-12, we screened for autoantibodies against interleukin-23 (anti-interleukin-23).

24 Interleukin-12 and interleukin-23 are inflammatory cytokines implicated in

25 ist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in

26 c agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of

27 ptor-induced secretion of interleukin-12 and interleukin-23 by DCs in an autocrine manner, promoted d

28 nized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit

29 Tumor necrosis factor-alpha, interleukin 23, chemokine C-C ligands 3 and 4, and decti

30 eous candidiasis, probably owing to impaired interleukin 23-dependent interleukin 17 immunity.

31 Moreover, interleukin-23-dependent expansion of ILC3s in mice and

32 the activity of these cytokines, inhibiting interleukin-23-dependent production of interleukin-17.

33 Interleukin-23 has been implicated in airway inflammatio

34 Cytokines interleukin-12 and interleukin-23 have been implicated in the pathogenesis

35 To determine whether blockade of the interleukin 23-helper T cell 17 (IL-23-TH17) pathway wit

36 or; 3982 (23.6%), with an interleukin 12 and interleukin 23 (IL-12/23) inhibitor; and 2711 (16.0%), w

37 Interleukin 23 (IL-23) and IL-17 have been linked to the

38 atus lung infection in the presence of lower interleukin 23 (IL-23) and IL-17A production in the lung

39 cteria requires the sequential generation of interleukin 23 (IL-23) and IL-22 to induce protective mu

40 Ltbr(-/-) mice lacked interleukin 23 (IL-23) and IL-22, which can regulate SFB

41 ol assembly of heterodimeric proteins, using interleukin 23 (IL-23) as a model.

42 resent in various nephritides in which serum interleukin 23 (IL-23) is elevated.

43 Interleukin 23 (IL-23) is integral to the pathogenesis o

44 Interleukin 23 (IL-23) is required for autoimmune inflam

45 Levels of interleukin 23 (IL-23) produced by PBMC from HIV-1-infec

46 ytokine interleukin 12p70 and an increase in interleukin 23 (IL-23) production by gp120-treated mDCs.

47 Here, we observed increased interleukin 23 (IL-23) protein levels in human colon bio

48 egies to examine the effect that blockade of interleukin 23 (IL-23) signaling had on GVH and GVL reac

49 Signaling of interleukin 23 (IL-23) via the IL-23 receptor (IL-23R) a

50 Interleukin 23 (IL-23) was essential for the accelerated

51 Expression of interleukin 23 (IL-23), IL-1 receptor I (IL-1RI), IL-17R

52 17 helper T cell (TH17)-associated cytokine interleukin 23 (IL-23), which was associated with positi

53 r 'imprinted' signaling via the receptor for interleukin 23 (IL-23R) in responding T cells to promote

54 Interleukin-23 (IL-23) and IL-17 are cytokines currently

55 ed to chronic inflammation, particularly via interleukin-23 (IL-23) and IL-17 signaling pathways.

56 Stress increased the TLO formation cytokines interleukin-23 (IL-23) and IL-22 followed by up-regulati

57 iciently low to impair cellular responses to interleukin-23 (IL-23) and partially IL-12, but not othe

58 Interleukin-23 (IL-23) and the recently discovered Th17

59 Serum concentrations of interleukin-23 (IL-23) are elevated and polymorphisms in

60 tion of LMP7 by PR-957 blocked production of interleukin-23 (IL-23) by activated monocytes and interf

61 this study, we have identified secretion of interleukin-23 (IL-23) by donor antigen-presenting cells

62 In particular, miR-29 downregulated interleukin-23 (IL-23) by targeting IL-12p40 directly an

63 re associated with SNPs in the IL-23R or the interleukin-23 (IL-23) cytokine itself and related downs

64 We sought to investigate the role of interleukin-23 (IL-23) deficiency, a cytokine important

65 Interleukin-23 (IL-23) is a heterodimeric cytokine that

66 Interleukin-23 (IL-23) is a pro-inflammatory cytokine re

67 Interleukin-23 (IL-23) is a proinflammatory cytokine mai

68 Interleukin-23 (IL-23) is an important proinflammatory c

69 Interleukin-23 (IL-23) is considered a critical regulato

70 Interleukin-23 (IL-23) is one of the key cytokines that

71 Experimental models have shown that interleukin-23 (IL-23) orchestrates innate and T cell-de

72 % CI, 1.10-2.63) and activating genes in the interleukin-23 (IL-23) pathway (odds ratio, 1.55; 95% CI

73 Here we report that interleukin-23 (IL-23) production by the thymic dendriti

74 accumulated, phagocytosis was impaired, and interleukin-23 (IL-23) production was reduced in Muc5b(-

75 ed by LPS/HI have elevated expression of the interleukin-23 (IL-23) receptor, a marker of early TH17

76 is mounting evidence for a critical role of interleukin-23 (IL-23) signaling in the pathogenesis of

77 that epithelial cell-intrinsic production of interleukin-23 (IL-23) triggers an inflammatory loop in

78 Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, si

79 Interleukin-23 (IL-23), a member of the IL-12 family, is

80 Interleukin-23 (IL-23), an IL-12 family cytokine, plays

81 ion of effector CD4(+) T cells stimulated by interleukin-23 (IL-23), but whether these cells are requ

82 We report here that interleukin-23 (IL-23), the cytokine most clearly tied t

83 Maintenance of the Th17 phenotype requires interleukin-23 (IL-23), whereas the Th1-promoting cytoki

84 In interleukin-23 (IL-23)-dependent colitis, there is exces

85 for eosinophils as crucial effectors of the interleukin-23 (IL-23)-granulocyte macrophage colony-sti

86 the context of increased microenvironmental interleukin-23 (IL-23).

87 responses, partly through the production of interleukin-23 (IL-23).

88 d the influence of morphine treatment on the interleukin-23 (IL-23)/IL-17 axis and related innate imm

89 Immunity to OPC is strongly dependent on the interleukin-23 (IL-23)/IL-17R axis, as mice and humans w

90 The interleukin-23 (IL-23)/T-helper 17 cell pathway is impli

91 d high affinity and selectivity to the human interleukin-23 (IL-23R) and IL-17 receptor A were used.

92 Human interleukin 12 and interleukin 23 (IL12/23) influence susceptibility or res

93 Levels of interleukin 23 (IL23) and T-helper (Th) 17 cell pathway

94 Interleukin 12 (IL12) and interleukin 23 (IL23) play key roles in inflammation, es

95 onoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the path

96 define a role for TLR-mediated production of interleukin-23 in immune cell homing and pathogenesis.

97 Whether targeting interleukin-23 in the treatment of asthma improves disea

98 clonal antibody targeting the p19 subunit of interleukin-23, in patients with moderately-to-severely

99 This action of GM-CSF is mediated by its interleukin-23-inducing activity rather than its role as

100 Interleukin-23 inhibition is effective in treating ulcer

101 gher-than-approved doses of risankizumab, an interleukin-23 inhibitor, for treatment of moderate-to-s

102 ling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-s

103 n 6, interleukin 10, IL-17A, interleukin 22, interleukin 23, interferon gamma, kynurenine, and trypto

104 s initiates a cytokine cascade that includes interleukin-23, interleukin-17, and ultimately granulocy

105 D patients did not produce excess amounts of interleukin-23, interleukin-17, or tumor necrosis factor

106 We had previously found a dominant interleukin-23-interleukin-17 signature at inflamed site

107 The discovery of CD4+ Th17 T cells and the interleukin-23/interleukin-17 axis has challenged existi

108 olded protein response and activation of the interleukin-23/interleukin-17 axis have been observed in

109 Activation of the interleukin-23/interleukin-17 axis in spondyloarthritis

110 cells and emerging data suggesting that the interleukin-23/interleukin-17 axis may be involved in th

111 -genome association studies suggest that the interleukin-23/interleukin-17 axis plays an important ro

112 beta and interleukin-6 are critical, whereas interleukin-23 is more important at later stages promoti

113 Interleukin-23 is thought to be critical to the pathogen

114 noclonal antibody against interleukin-12 and interleukin-23, is unknown.

115 we compared guselkumab (CNTO 1959), an anti-interleukin-23 monoclonal antibody, with adalimumab in p

116 ty, humanised, IgG1 kappa antibody targeting interleukin 23 p19 that represents an evolving treatment

117 sted clinical improvement with inhibition of interleukin 23 p19.

118 nflammatory cytokine production, depended on interleukin-23 p19 secretion, whereas interleukin-12 p35

119 eron-gamma as well as interleukin-12 p40 and interleukin-23 p40 secretion.

120 nes that encode factors that function in the interleukin-23 pathway have been associated with a numbe

121 The interleukin-23 pathway is implicated genetically and bio

122 otably, genes whose products function in the interleukin-23 pathway, and transcription factors, inclu

123 this pathway inhibits Th17 cells by limiting interleukin 23 production.

124 NF), major histocompatibility complex (MHC), interleukin 23 receptor (IL23R) and protein tyrosine pho

125 Here, we provide evidence that the interleukin 23 receptor (IL23R) expressed by tumor-infil

126 as well as murine models have shown that the interleukin 23 receptor (IL23R) pathway plays a pivotal

127 cleotide polymorphisms (SNPs) mapping to the interleukin-23 receptor (IL-23R) and IL-12beta genes wit

128 These cells required interleukin-23 receptor (IL-23R) and IL-1R but not IL-6R

129 ous European studies suggest NOD2/CARD15 and interleukin-23 receptor (IL-23R) donor or recipient vari

130 Interleukin-23 receptor plays a critical role in inducin

131 Selective blockade of the interleukin-23 receptor with the targeted oral peptide i

132 s and genetically predicted body mass index, interleukin-23 receptor, and eight circulating proteins.

133 eted oral peptide that selectively binds the interleukin-23 receptor, compared with both placebo and

134 eted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the

135 aily oral administration, treatment with the interleukin-23-receptor antagonist peptide JNJ-77242113

136 JNJ-77242113 is a novel, orally administered interleukin-23-receptor antagonist peptide that selectiv

137 IL-23 (interleukin 23) regulates immune responses against patho

138 Interleukin 12 and interleukin 23 share the same subunit, p40, and are both

139 Mirikizumab, a p19-directed antibody against interleukin-23, showed efficacy in the treatment of ulce

140 r antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine product

141 targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleuki

142 ed as a major source of IL-22 in response to interleukin 23 stimulation.

143 ts p40 and p35) shares a common subunit with interleukin-23 (subunits p40 and p19).

144 In humans, interleukin-23 synergizes with interleukin-6 and interle

145 ophagy (eg, ATG16L1, IRGM), and genes in the interleukin-23-T helper cell 17 pathway indicate the imp

146 of pivotal mucosal cytokines, including the interleukin-23/T helper 17 cytokine, interleukin-22.

147 pathways, the most prominent of which is the interleukin-23/Th17 axis.

148 e is known about the effect of specific anti-interleukin-23 therapy, as compared with established ant

149 psoriasis can be achieved with specific anti-interleukin-23 therapy.

150 umor necrosis factor and anti-interleukin-12/interleukin-23 treatment on SB and colonic ACE2 expressi

151 Therefore, selective blockade of interleukin-23 via inhibition of p19 might be a viable t

152 patients with thymoma, the presence of anti-interleukin-23 was associated with infection status in 7

153 nfections, the presence of neutralizing anti-interleukin-23 was associated with severe, persistent op

154 Overall, neutralizing anti-interleukin-23 was detected in 30 of 116 patients (26%)

155 elevated immunoglobulin A autoantibodies and interleukin-23 was observed.

156 Anti-interleukin-23 was present in 6 of 32 patients (19%) wit

157 l antibody and anti-p19 subunit inhibitor of interleukin-23, was demonstrated in a phase 2a trial in

158 ody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous inductio

159 tion (MCP1, tumor necrosis factor-alpha, and interleukin-23) were significantly attenuated, whereas a

160 anism involves GM-CSF-mediated production of interleukin-23, which increases apoptosis susceptibility

161 To validate the potential role of anti-interleukin-23 with respect to opportunistic infection,

162 In this phase 2 trial, selective blockade of interleukin-23 with risankizumab was associated with cli